Baylx receives US FDA clearance of Covid-19 IND application for umbilical cord tissue mesenchymal stem cells product

This article was originally published here

Mesenchymal stem cells hold great promise to treat COVID-19 patients due to their potential in inhibiting the overactivated immune system and promoting the recovery of pulmonary and other

The post Baylx receives US FDA clearance of Covid-19 IND application for umbilical cord tissue mesenchymal stem cells product appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply